Impact ledger
Johnson & Johnson (JNJ): the developments shaping its investment case
Follow the evidence affecting Johnson & Johnson's valuation assumptions, demand outlook, margins. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Johnson & Johnson · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-18
10-Year Treasury yield approaches 5.0%, compressing defensive dividend risk premiums
Channel: Increased competition for passive income from risk-free assets; higher discount rates reduce present value of future dividends.
Bearish· 1-3m
2026-09-15 · 7 reports
Citadel increases AbbVie stake over 500% amid institutional yield rotation
Channel: Second-order effect: Similar characteristics (large-cap, healthcare, dividend payer) make it a likely beneficiary of the same institutional yield rotation.
Bullish· 1-3m
2026-09-15 · 2 reports
Citadel Expands AbbVie Stake by Over 500% in Q2 2026
Channel: Sector-wide positive sentiment for defensive healthcare stocks; potential for capital rotation into stable pharma.
Bullish· 1-3m
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-09-12 | multiple | Bullish | Target re-rates to bid premium until close. |
| 2026-07-15 | revenue | Bullish | Company raised 2026 guidance to $101.1 Billion midpoint based on strong operational performance. |
| 2026-07-15 | revenue | Bullish | Company raised 2026 sales guidance to $101.1 Billion at the midpoint. |
| 2026-07-15 | revenue | Bullish | Company raised 2026 guidance with estimated reported sales of $101.1 Billion. |
| 2026-07-15 | share_count | Bullish | Stock component of consideration dilutes existing acquirer holders. |
| 2026-07-15 | net_debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. |
| 2026-07-15 | revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. |
| 2026-07-15 | margin | Bullish | Company increased adjusted EPS guidance by $0.13 to $11.68. |
| 2026-07-15 | revenue | Bullish | Company raised 2026 guidance to estimated reported sales of $101.1 Billion. |
Event impact log
71 events mapped to JNJ since 2026-08-11. Evidence through 2026-09-26.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-26 | C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data | Potential future competition in the multiple myeloma market, specifically for elranatamab, if cemsidomide progresses. | watch | 3-12m | 0.20 |
| 2026-09-26 | C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS | Indirect competitive landscape implications in multiple myeloma. | watch | 3-12m | 0.20 |
| 2026-09-24 | Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder | Potential competitive landscape shift in mental health therapeutics. J&J has a broad pharmaceutical portfolio and may be interested in or impacted by new treatments for anxiety disorders. | watch | 3-12m | 0.10 |
| 2026-09-24 | Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel; Rolling BLA Submission on Track for Q4 2026 | Potential competitive pressure or validation of the CAR T cell therapy approach in autoimmune diseases. J&J has an interest in cell therapies. | watch | 3-12m | 0.20 |
| 2026-09-24 | HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO | Increased competitive pressure in the EGFR-mutated NSCLC market, particularly for patients developing MET-driven resistance, potentially impacting future market share for competing therapies. | Bearish | 3-12m | 0.30 |
| 2026-09-21 | Alkermes Announces Positive Phase 1b Results for ALKS 7290 in Adults With ADHD | Potential future competition in the ADHD market, particularly for novel mechanisms of action. | watch | 1-5y | 0.20 |
| 2026-09-21 | Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix | Indirect competitive and investor sentiment. As a diversified healthcare giant, JNJ's pharmaceutical segment competes with BMY. BMY's strong performance in new drug adoption could subtly influence investor expectations for innovation across the industry. | mixed | 3-12m | 0.10 |
| 2026-09-21 | Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth | Similar to PFE, BMY's successful product transition offers a benchmark for other diversified healthcare giants managing their own drug pipelines and patent expirations. It could also intensify competition. | mixed | 1-3m | 0.30 |
| 2026-09-21 | Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60% | Indirect sector sentiment and comparative strategic execution. | watch | 3-12m | 0.20 |
| 2026-09-21 | Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2 | Diversified healthcare conglomerate with a significant pharmaceutical segment. BMY's performance offers insights into the competitive landscape and investor appetite for pharmaceutical innovation. | mixed | 3-12m | 0.40 |
| 2026-09-19 | Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity | Potential competitive pressure on J&J's long-acting injectable antipsychotics (e.g., Invega Sustenna/Trinza) due to UZEDY's demonstrated superiority in real-world adherence and cost-effectiveness. | Bearish | 1-3m | 0.40 |
| 2026-09-19 | Teva presents real-world data showing UZEDY treatment continuity advantage | UZEDY competes in the schizophrenia treatment market. Improved data for Teva's UZEDY could potentially increase competitive pressure on J&J's long-acting injectable antipsychotics (e.g., Invega Sustenna/Trinza), potentially affecting their market share or pricing power over time. | watch | 3-12m | 0.20 |
| 2026-09-19 | Teva real-world data demonstrates UZEDY reduces emergency care and medical costs | Increased competitive pressure on J&J's long-acting injectable schizophrenia treatments (e.g., Invega Sustenna/Trinza) due to Teva's UZEDY demonstrating superior real-world outcomes and cost-effectiveness, potentially leading to slower growth or market share erosion. | Bearish | 3-12m | 0.40 |
| 2026-09-19 | Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity | Increased competitive pressure on long-acting injectable antipsychotics, potentially impacting market share and pricing. | Bearish | 3-12m | 0.40 |
| 2026-09-19 | Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions | Increased competitive pressure and potential market share erosion for their long-acting injectable antipsychotics (e.g., Invega Sustenna/Trinza) due to UZEDY's demonstrated superior outcomes and cost profile. | Bearish | 3-12m | 0.50 |
| 2026-09-19 | Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilization | Increased competitive pressure in the schizophrenia treatment market from UZEDY's improved clinical profile and potential for enhanced formulary access, potentially impacting market share for competing products. | Bearish | 3-12m | 0.30 |
| 2026-09-19 | Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables | Increased competitive pressure on long-acting injectable antipsychotics, potentially leading to market share erosion or pricing pressure for their similar products. | Bearish | 1-3m | 0.40 |
| 2026-09-18 | 10-Year Treasury yield approaches 5.0%, compressing defensive dividend risk premiums | Increased competition for passive income from risk-free assets; higher discount rates reduce present value of future dividends. | Bearish | 1-3m | 0.60 |
| 2026-09-17 | Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways | Similar to Pfizer, J&J has a broad pharmaceutical presence and could benefit from new opportunities but also face increased competition. | mixed | 3-12m | 0.45 |
| 2026-09-15 | Citadel increases AbbVie stake over 500% amid institutional yield rotation | Second-order effect: Similar characteristics (large-cap, healthcare, dividend payer) make it a likely beneficiary of the same institutional yield rotation. | Bullish | 1-3m | 0.60 |
| 2026-09-15 | Citadel Expands AbbVie Position Over 500% Amid Defensive Rotation and Dividend Demand | Broader sector rotation into defensive healthcare, dividend-paying stocks, flight to quality. | Bullish | 1-3m | 0.50 |
| 2026-09-15 | Citadel Expands AbbVie Stake by Over 500% in Defensive Rotation | Second-order effect: Potential for broader defensive sector rotation. If Citadel is increasing exposure to ABBV, other large-cap pharmaceutical/healthcare companies might also see increased interest. | watch | 1-3m | 0.30 |
| 2026-09-15 | Citadel Expands AbbVie Position Over 500% as Defensive Dividend Demand Rises | Increased investor demand for defensive, dividend-paying stocks, particularly in the healthcare sector. JNJ is a well-known dividend aristocrat. | Bullish | 1-3m | 0.50 |
| 2026-09-15 | Citadel Expands AbbVie Position Over 500% in Q2 Amid Defensive Rotation | Second-order effect: As a large-cap pharmaceutical company with a strong dividend and defensive characteristics, JNJ is likely to benefit from the same thematic rotation of institutional capital seeking safety and yield. | Bullish | 1-3m | 0.60 |
| 2026-09-15 | Citadel increases AbbVie position by over 500% amid defensive yield rotation | Peer in defensive healthcare/biopharma sector, likely to benefit from similar defensive yield rotation. | Bullish | 1-3m | 0.50 |
| 2026-09-15 | Citadel Expands AbbVie Stake by Over 500% in Q2 2026 | Sector-wide positive sentiment for defensive healthcare stocks; potential for capital rotation into stable pharma. | Bullish | 1-3m | 0.50 |
| 2026-09-15 | Citadel expands AbbVie stake over 500% in Q2 defensive positioning move | Sector-wide positive sentiment spillover for large-cap, defensive pharmaceutical companies with strong dividends, as institutional investors seek similar characteristics. | Bullish | 1-3m | 0.50 |
| 2026-09-15 | Citadel Expands AbbVie Holding by Over 500% as Defensive Dividend Yield Draws Capital | Similar to ABT, JNJ is a large-cap, diversified healthcare company with a strong dividend history, often considered a defensive play. The capital flow into ABBV could indicate a broader institutional preference for such assets, potentially benefiting JNJ as well. | watch | 1-3m | 0.30 |
| 2026-09-15 | Citadel Expands AbbVie Stake Over 500% as High Yields Drive Defensive Rotation | Second-order effect: Sector rotation into defensive healthcare, high-quality cash flow, and dividend-paying stocks. JNJ shares similar characteristics to ABBV. | Bullish | 1-3m | 0.60 |
| 2026-09-14 | The Cooper Companies Lowers Full-Year Organic Guidance on Channel Destocking | Second-order effect: J&J's Vision Care segment (Acuvue contact lenses) operates in the same market as CooperVision. Destocking at distributors could indicate broader market trends or competitive pressures. | watch | 1-3m | 0.30 |
| 2026-09-14 | Cooper Companies Drops 14.6% as Channel Destocking Cuts Full-Year Guidance | Second-order effect: J&J's Vision Care segment (Acuvue contact lenses) operates in the same market and utilizes similar distribution channels. Destocking at distributors for one major player could indicate a broader trend affecting others. | watch | 1-3m | 0.40 |
| 2026-09-13 | Cooper Companies Cuts Organic FY Guidance on U.S. Channel Destocking | Second-order effect: Potential for similar channel destocking in other medical device or consumer health segments, particularly those with significant U.S. distributor networks. J&J has a large Vision Care segment (Acuvue). | watch | 1-3m | 0.30 |
| 2026-09-13 | Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoY | Increased competition in the immunology market from Eli Lilly's growing portfolio, potentially impacting J&J's immunology product sales. | Bearish | 3-12m | 0.40 |
| 2026-09-13 | Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 on Taltz and New Launches | Competitive dynamics within the broader immunology market. J&J has a significant immunology franchise (e.g., Stelara, Tremfya, Darzalex), and LLY's strong performance signals an increasingly competitive environment for market share and new patient starts. | mixed | 3-12m | 0.40 |
| 2026-09-13 | The Cooper Companies Cuts Organic Guidance to Flat-to-Down 2% on Channel Destocking | Second-order effect: As a major player in the vision care market (Acuvue contact lenses), J&J could potentially face similar, albeit less severe, channel destocking pressures in the U.S. if the issue is industry-wide rather than company-specific. | watch | 1-3m | 0.30 |
| 2026-09-13 | Cooper Companies Cuts FY Guidance on U.S. Channel Destocking | Second-order effect: J&J's MedTech segment, including vision care (Acuvue), could face similar inventory adjustments from distributors if the trend observed by Cooper Companies is systemic rather than company-specific. | watch | 1-3m | 0.30 |
| 2026-09-13 | Cooper Companies Drops 14.6% on US Channel Destocking and Guidance Cut | Indirect read-across for its vision care segment (Acuvue contact lenses) and broader medical device portfolio, though JNJ's diversified nature mitigates impact. | watch | 1-3m | 0.20 |
| 2026-09-13 | Eli Lilly Immunology Division Reaches $2.6 Billion Revenue in H1 2026 | Increased competitive pressure in the immunology market from a strong player like Eli Lilly could impact market share or pricing power for J&J's immunology portfolio. | mixed | 3-12m | 0.40 |
| 2026-09-12 | Eli Lilly Immunology Division Reaches $2.6B in H1 2026 on Taltz and New Labels | Increased competitive pressure in the immunology market, particularly for drugs like Stelara and Tremfya. | mixed | 3-12m | 0.30 |
| 2026-09-12 | Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A | Intensified competition in the immunology therapeutic area, where J&J has significant market presence (e.g., Stelara, Tremfya), potentially affecting future growth rates or market share. | mixed | 3-12m | 0.30 |
Continue this research
Build your Johnson & Johnson investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the JNJ entity page →